Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 66, n° 4
page 689 (avril 2012)
Doi : 10.1016/j.jaad.2011.09.038
Notes & Comments

Response to the letter to editor re: “Methotrexate and psoriasis: Consensus conference”
 

Alan Menter, MD
Baylor Institute of Research, Dermatology Research Center, Baylor University Medical Center, Dallas, Texas 

Correspondence to: Alan Menter, MD, Baylor Institute of Research, Dermatology Research Center, Baylor University Medical Center, 3900 Junius St, Suite 125, Dallas, TX 75246

 Chairman of American Academy of Dermatology Psoriasis Guidelines Committee
 Funding sources: None.
 Disclosure: Dr Menter has served as a consultant, investigator, speaker, or advisory board member for Abbott, Allergan, Amgen, Astellas, Asubio, Celgene, Centocor, DUSA, Eli Lilly, Galderma, Genentech, Novartis, Novo Nordisk, Pfizer, Promius, Stiefel, Syntrix Biosystems, Warner Chilcott, and Wyeth.


Top of the page

© 2011  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@